BlackRock Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

BlackRock Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.09M	Buy	352,185 +13,989	+4%	+$246K	0.01%	1131
2016 Q3	$7.79M	Buy	338,196 +15,106	+5%	+$288K	0.01%	959
2016 Q2	$5.36M	Buy	323,090 +319,635	+9,251%	+$6.45M	0.01%	1078
2016 Q1	$55K	Buy	3,455 +1,042	+43%	+$18.5K	﹤0.01%	3135
2015 Q4	$78K	Sell	2,413 -190,278	-99%	-$8.24M	﹤0.01%	3036
2015 Q3	$8.12M	Buy	+192,691	New	+$9.09M	0.01%	879

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock Advisors's GBT Position: Q4 2016 in Review

BlackRock Advisors increased its Global Blood Therapeutics, Inc. (GBT) stake by 4.1% in Q4 2016, buying an estimated $246K and bringing the position to 352,185 shares worth $5.09M. The position accounts for 0.01% of the portfolio, ranked #1131.

BlackRock Advisors first reported a position in GBT in Q3 2015 and has held it in 6 quarters since. The position peaked at $8.12M in Q3 2015. 96 funds tracked by Wall St. Rank hold GBT as of Q4 2016.

BlackRock Advisors held 352,185 shares of Global Blood Therapeutics, Inc. worth $5.09M as of Q4 2016.
BlackRock Advisors bought 13,989 Global Blood Therapeutics, Inc. shares in Q4 2016, an estimated $246K.
Global Blood Therapeutics, Inc. made up 0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1131 holding.
BlackRock Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and has held it in 6 quarters since.
BlackRock Advisors's Global Blood Therapeutics, Inc. position peaked at $8.12M in Q3 2015.
96 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.